Adverse Event Profile Patents May Be New Front In Brand/Generic Disputes

17 Dec 2001

• By The Pink Sheet

Adverse event profile patents offer the potential for manufacturers to claim a "perpetual monopoly" on drugs, Classen Immunotherapies CEO John Classen, MD, told a Center for Business Intelligence conference Nov. 30 in Washington, D.C

Adverse Event Profile Patents May Be New Front In Brand/Generic Disputes

More from Archive

More from Pink Sheet